Principal Investigator
Ping Huang
Zhejiang Cancer Hospital
Total Trials
2
As PI
2
Completed
0
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
DRUG(1)
MIXED(1)
Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
1 trial
phase_3
zhejiang-cancer-hospitalChemotherapy
1 trial
zhejiang-cancer-hospital
2 unique interventions2 categories
Analytics
Trial Phases
Phase 31
Trial Status
Recruiting1
Other1
Role Distribution
Principal Investigator2
PI Rate100%
Activity Timeline
Clinical Trials (2)
NCT05550090Unknown
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBCMetastatic Breast Cancer in the Liver
Principalinvestigator
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Principalinvestigator
Research Network
Collaboration Network
1 collaborators·0 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Zhejiang Cancer Hospital
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
1 similar investigators found
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
NCT05550090PrincipalInvestigator
Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC
Metastatic Breast Cancer in the Liver
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
All 2 trials loaded